Indeed, treatments with SGLT inhibitors phlorizin and LX4211 (sotagliflozin, approved in the European Union for type 1 diabetes mellitus) reduced the 2-NBDG uptake in H322/ER and HCC827/ER clones under low glucose culture conditions (Fig. 2f and Supplementary Fig. S3i) without affecting GLUT3 activity (Supplementary Fig. S3j). This evidence concerns the gene SLC2A3 and diabetes mellitus.